State Street Corp increased its holdings in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) by 19.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 839,218 shares of the biopharmaceutical company’s stock after buying an additional 138,112 shares during the quarter. State Street Corp owned about 1.53% of Dynavax Technologies worth $8,099,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in DVAX. Patriot Financial Group Insurance Agency LLC lifted its position in Dynavax Technologies by 16.5% during the second quarter. Patriot Financial Group Insurance Agency LLC now owns 12,000 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 1,700 shares during the period. Legal & General Group Plc lifted its position in Dynavax Technologies by 18.5% during the second quarter. Legal & General Group Plc now owns 12,501 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 1,950 shares during the period. Bank of America Corp DE lifted its position in Dynavax Technologies by 2.3% during the first quarter. Bank of America Corp DE now owns 20,356 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 456 shares during the period. Wall Street Access Asset Management LLC purchased a new position in shares of Dynavax Technologies in the 2nd quarter worth about $124,000. Finally, CAPROCK Group Inc. purchased a new position in shares of Dynavax Technologies in the 2nd quarter worth about $134,000. Hedge funds and other institutional investors own 70.61% of the company’s stock.

Dynavax Technologies Corporation (DVAX) opened at $19.50 on Thursday. Dynavax Technologies Corporation has a twelve month low of $3.70 and a twelve month high of $24.45.

Dynavax Technologies (NASDAQ:DVAX) last posted its earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.15. Dynavax Technologies had a negative return on equity of 65.97% and a negative net margin of 1,177.60%. The business had revenue of $0.05 million during the quarter, compared to analyst estimates of $0.28 million. During the same quarter last year, the firm earned ($0.90) earnings per share. The company’s revenue for the quarter was down 68.8% compared to the same quarter last year. equities analysts predict that Dynavax Technologies Corporation will post -1.72 EPS for the current fiscal year.

A number of research firms have recently commented on DVAX. Cantor Fitzgerald raised their price objective on Dynavax Technologies from $24.00 to $25.00 and gave the stock an “overweight” rating in a report on Thursday, November 9th. Cowen restated a “buy” rating and issued a $30.00 price objective on shares of Dynavax Technologies in a report on Friday, November 3rd. Royal Bank Of Canada restated an “outperform” rating and issued a $28.00 price objective (up from $26.00) on shares of Dynavax Technologies in a report on Monday, September 25th. ValuEngine upgraded Dynavax Technologies from a “sell” rating to a “hold” rating in a report on Thursday, September 7th. Finally, William Blair restated an “outperform” rating and issued a $30.00 price objective on shares of Dynavax Technologies in a report on Wednesday, August 9th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Dynavax Technologies presently has a consensus rating of “Buy” and an average price target of $25.17.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/state-street-corp-buys-138112-shares-of-dynavax-technologies-corporation-dvax/1734217.html.

Dynavax Technologies Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Corporation (NASDAQ:DVAX).

Institutional Ownership by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.